Lenalidomide Analogs for the Treatment of Neurodegenerative Disorders and Cancer

Novel thalidomide analogs and their use as immunomodulatory agents are disclosed in this invention by scientists at the National Institute on Aging (NIA). These therapeutic compounds could reduce chronic systemic and central nervous system inflammation.NIH Ref. No.: E-045-2012Advantages: • Effective smaller molecular weight compound that can enter brain among current agents• Experimental therapeutic to reduce inflammation systematically and within the brain• More effective in reducing proinflammatory cytokines than existing agentApplications: • Treatment for blood disorders (myelodysplastic syndrome), cancer (multiple myeloma), inflammatory processes and erythema• Immunomodulatory agents• Reduce chronic systemic and central nervous system inflammationDevelopment Status: ClinicalUpdated On: Dec 6, 2017Provider Classifications: Date Published: Wednesday, December 6, 2017Publications: Patent Application: 15/457,156Patent Authority: 9,623,020Patent Number: 8,927,7259,084,783Licensing Contacts: Lead Inventor: Inventor Lab URL: https://irp.nih.gov/pi/nigel-greigInv Is lead: LPM Phone: [phone]LPM Email: [e-mail] Classification: TherapeuticsDTDT Description: TherapeuticsPatent Issue Date: 2015-01-06T00:00:002015-07-21T00:00:002017-04-18T00:00:00Publication Link: https://www.ncbi.nlm.nih.gov/pubmed/21658960Publication Caption: PMIDPublication Tit...

Source: NIH OTT Licensing Opportunities - December 6, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research